Event details
On the back of the National Point of Care Testing guidance issued in May by the IBMS, RCPath and ACB. This webinar will explore the use case of rapid diagnostic testing to Care, Monitor and Protect.
The purpose of a POCT service is to enable the delivery of high quality, accessible diagnostics at the point of need for clinical services, improving clinical outcomes and enhancing the patients’ healthcare experience. The aim should be to ensure that POCT services nationally utilise (and inform) advances in technology to innovate the way in which patients can access diagnostics and clinical services.
Technology plays an important part of the patient pathway and in 2022 The World Health Organisation (WHO) published The Target Product Profile (TPP) for readers of rapid diagnostic tests detailing the preferred product characteristics and target regimen profiles.
The webinar will provide a guide for commissioners, NHS settings and community pharmacies delivering NHS services. The NHS Long Term Plan highlights the importance of patients receiving care closer to home, shifting from a traditional model of hospital-based services towards a more adaptive community-based approach.
Learn about
- Previous case studies of how Testing to Care, Monitor and Protect has been robustly rolled out across the NHS. Issues faced and how they were overcome.
- Impact of digital readers when combined with high-quality lateral flow tests in a clinical setting
- How The Target Product Profile (TPP) for readers of rapid diagnostic tests was developed according to a process based on the WHO Target Product Profiles, Preferred Product Characteristics, and Target Regimen Profiles.
Speakers
- Dr George Newham PhD, Research and Development Manager, SureScreen Diagnostics
- Dr Rahul Batra, Clinical Innovations and Disruptive Technologies Lead in the Centre for Clinical Infection and Diagnostics Research at Guy’s and St Thomas’ Hospital
- Julie Hart, NHS Pathway Transformation and Market Access Expert: Diagnostics and Artificial Intelligence
- Dr Andrew Botham, Chief Scientific Officer - TestCard